Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics, a clinical-stage precision medicine company focused on cancer and genetic disease therapies, announced the pricing of an underwritten offering of approximately 22.9 million shares at $12.00 each, expected to raise gross proceeds of about $275 million. The offering will finance ongoing clinical trials including their lead asset z…